MAR 3 1 2004

2

FORM PTO-1449/A and B (Modified

Sheet

INFORMATION DISCLE STATEMENT BY APPLICANT

of

APPLICATION NO.: 09/674,593

DOCKET NO.: L0461.70099US

INT'L. FILING DATE: May 13, 1999

CONFIRMATION NO.: 9143

APPLICANT: Van den Eynde et al

GROUP ART UNIT: 1642

EXAMINER: YU, Misook

U.S. PATENT DOCUMENTS

Examiner's	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or of issue of Cited Document	
Initials#		Number	Kind Code	Document	MM-DD-YYY	
my	A1	5,342,774		Boon et al.	08-30-1994	
ì	A2	5,405,940		Boon et al.	04-11-1995	
	A3	5,629,166		van der Bruggen et al.	05-13-1997	
	A4	5,620,886		Brichard et al.	04-15-1997	
	A5	5,571,711		van der Bruggen et al.	11-05-1996	
	A6	5,610,013		Van den Eynde et al.	03-11-1997	
	A7 ⁻	5,587,289		Lurquin et al.	12-24-1996	
	A8	5,589,334		Coulie et al.	12-31-1996	
	A9	5,487,974		Boon-Falleur	01-30-1996	
	A10	5,683,886		van der Bruggen et al.	11-04-1997	
	All	5,648,226		Van den Eynde et al.	07-15-1997	
	A12	5,997,870		Coulie et al.	12-07-1999	
4	A13	5,821,122		Guilloux et al.	10-13-1998	

FOREIGN PATENT DOCUMENTS

Examiner's	Cite No.	Foreign Patent Document		nent	Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
Initials#		Office/ Country	Number	Kind Code	(not necessary) Cited Doc	Cited Document MM-DD-YYYY	(Y/N)
my	B1	wo	92/20356		Ludwig Institute for Cancer Research	26 Nov 1992	
	B2	wo	96/29409		Ludwig Institute for Cancer Research	26 Sep 1996	
Į.	B3	wo	96/10577		Ludwig Institute for Cancer Research	11 Apr 1996	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's	miner's Cite Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item		Translation
Initials# No		(book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s),	
	,	publisher, city and/or country where published.	
my	C1	TRAVERSARI et al., "A Nonapeptide Encoded by Human Gene MAGE-1 is Recognized on HLA-	1
		A1 by Cytolytic T Lymphocytes", J. Exp. Med. 176:1453-1457, 1992	
1	C2	VAN DER BRUGGEN et al., "A Gene Encoding an Antigen Recognized by Cytolytic T	
		Lymphocytes on a Human Melanoma," Science 25: 1643-1647, 1991	
	C3	DE PLAEN et al., "Structure, Chromosomal Localization, and Expression of 12 Genes of the MAGE	
		Family," Immunogenetics 40:360-369, 1994	
	C4	GenBank accession number AA863443	
	C5	GenBank accession number AA004587	
	C6	BROUWENSTIJN et al., "Renal-Cell Carcinoma-Specific Lysis by Cytotoxic T-Lymphocyte Clones Isolated from Peripheral Blood Lymphocytes," Int. J. Cancer 68:177-182, 1996	

misorch y 6/5/04

FORM PTO-1449/A and B (Modified) MAR 3 1 2004 INFORMATION DISCLOSURE STATEMENT BY APPENDING

of

Sheet

2

APPLICATION NO.: 09/674,593	DOCKET NO.: L0461.70099US	
INT'L. FILING DATE: May 13, 1999	CONFIRMATION NO.: 9143	
APPLICANT: Van den Eynde et al		
CROUD ART LINET. 1642	EVAMINED: VII Missole	

Examiner's	Cite	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item	Translation
Initials#	No	(book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	(Y/N)
ny	C7	GAUGLER et al., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes," <i>Immunogenetics</i> 44:323-330, 1996	
	C8	RAMMENSEE et al., "MHC Ligands and Peptide Motifs: First Listing," <i>Immunogenetics</i> 41:178-228, 1995	
	С9	VAN DEN EYNDE, et al., "A New Antigen Recognized by Cytolytic T Lymhocytes on a Human Kidney Tumor Results from Reverse Strand Transcription; <i>J. Exp. Med.</i> , Rockefeller Univ. Press, Vol. 190, Number 12, December 20, 1999, pgs. 1793-1799	

EXAMINE R 1	DATE CONSIDERED / /
misorh 2	6/5/04

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).